Spark Therapeutics, Inc. (ONCE) stock prices updated...
 

Spark Therapeutics, Inc. stock price

Spark Therapeutics, Inc. latest news:


  • 01/12/2018 10:51:16

    Spark's planned price for Luxturna gene therapy for rare blindness too high -ICER

    The proposed price for Spark Therapeutics Inc's (ONCE) groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.

  • 01/12/2018 09:57:51

    BRIEF-ICER Says Spark Therapeutics Gene Therapy Price Too High

    Spark Therapeutics Inc(ONCE): * INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW SAYS SPARK THERAPEUTICS LUXTURNA GENE THERAPY PRICE FAR TOO HIGH. * ICER SAYS $850,000 PRICE FOR LUXTURNA BLINDNESS TREATMENT SHOULD BE 75-82 PERCENT LOWER BASED ON VALUE ASSESSMENT. * ICER RECOMMENDS LUXTURNA PRICE BETWEEN $153,000 AND $217,000 FOR ONE-TIME GENE THERAPY Source text for Eikon: Further company coverage:

  • 01/08/2018 16:28:29

    BRIEF-Spark Therapeutics To Begin Program In Pompe Disease

    * SPARK THERAPEUTICS CEO SAYS PLANS TO BEGIN PROGRAM IN POMPE DISEASE

  • 01/03/2018 11:45:59

    AveXis could be lifted by rival Spark Therapeutics' pricing scheme for gene therapy: RBC

    Biotech AveXis Inc. could benefit, if indirectly, from payment arrangements set up by rival Spark Therapeutics Inc. for its $850,000-a-patient gene therapy Luxturna, RBC Capital Markets analyst Brian Abrahams said on Wednesday. AveXis, which is developing its AVXS-101 gene therapy as a one-time treatment for spinal muscular atrophy, saw shares decline 3.6% in heavy Wednesday trade. AVXS-101, if approved, could cost as much as $2 million per treatment, Abrahams said. The payment schemes set up by Spark, intended to make Luxturna's record-setting pricetag more palatable to health care payers, "helps set the stage for AVXS's '101 and other gene therapies," Abrahams said. "We note this strategy is in distinct contrast to what had taken place with other one-time treatments as in HCV, and believe that this more proactive approach is more likely to ensure the buy-in of key constituents (rather than generate a backlash)." Positive results from a phase 1 trial of AVXS-101 were published in the New England Journal of Medicine in November, and Abrahams said that the Food and Drug Administration might consider accelerated approval. Abrahams also raised his price target for AveXis from $97 to $99 on Wednesday, citing the success of Biogen's spinal muscular atrophy therapy Spinraza, among other factors. AveXis shares have surged 8.4% over the last three months, compared with a 6.9% rise in the S&P 500 and a 9.6% rise in the Dow Jones Industrial Average .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 01/03/2018 09:07:58

    UPDATE 2-Spark to charge $850,000 per patient for blindness gene therapy

    Jan 3 (Reuters) - Spark Therapeutics Inc said on Wednesday it will charge $850,000 per patient for its breakthrough gene therapy to treat a rare form of blindness, a lower than expected price that the company said reflects patient and insurer concerns about access and cost.

  • 12/19/2017 09:07:43

    Spark Therapeutics shares rise on FDA approval of new gene therapy for blindness

    Spark Therapeutics Inc. shares rose 3% in heavy morning trade Tuesday after the company's gene therapy Luxturna was approved by the Food and Drug Administration for a rare type of inherited vision loss. Just one administration of the therapy could treat the disease, making it a major scientific breakthrough. The approval had been widely expected after an FDA committee recommended it in October, and was heralded by FDA Commissioner Scott Gottlieb as "another first in the field of gene therapy." The next, major question for the therapy is price, with some analysts projecting the cost could come close to $1 million. Gene therapies, the first of which was approved this past summer, are expected to challenge existing U.S. payment structures with their price tags, which are extremely high and cover a one-time treatment. Luxturna was approved for individuals with confirmed biallelic RPE65 mutation-associated retinal dystrophy, which is part of a group of eye disorders caused by gene mutations, can cause complete blindness in some cases and affects about 1,000 to 2,000 people in the U.S. Spark shares have plummeted 41.5% over the last three months, compared with a 7.2% rise in the S&P 500 and a 10.8% rise in the Dow Jones Industrial Average .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 12/11/2017 14:26:32

    Apple and Chesapeake Energy rise; Spark Therapeutics sinks

    Apple and Chesapeake Energy climb while Spark Therapeutics and Scana drop

  • 12/11/2017 14:04:46

    Goldcorp, Spark Therapeutics Tumble into Monday’s 52-Week Low Club


  • 12/06/2017 15:16:19

    Gene-therapy approach to hemophilia finds success in study, Spark stock surges

    Spark Therapeutics Inc. stock surged Wednesday afternoon after the company announced positive results from a study of a gene-therapy approach to hemophilia. The drug, developed and tested in a collaboration with Pfizer Inc. , involves a single injection meant to help those suffering from hemophilia B, a disease that keep blood from clotting and is typically treated with regular and costly infusions. The study followed 10 adult males for 492 weeks and found that the number of episodes of bleeding decreased from an average of 11.1 a year before administration to 0.4 per year after, while infusions were reduced by 99%. The results were published in The New England Journal of Medicine on Wednesday, the companies said in a news release. Spark shares jumped as much as 9% in late trading after the announcement Wednesday, while Pfizer shares were unchanged.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 11/10/2017 15:26:29

    BRIEF-Spark Therapeutics says 3-year follow-up phase 3 data provide additional information on Luxturna

    Spark Therapeutics Inc(ONCE): * Three-Year follow-up phase 3 data provide additional information on efficacy, durability and safety of investigational Luxturna in patients with biallelic RPE65-mediated inherited retinal disease Source text for Eikon: Further company coverage:

  • More trends:

    Spartan Motors, Inc.SPAR | SpartanNash CompanySPTN | Spectrum Pharmaceuticals, Inc.SPPI | Speed Commerce, Inc.SPDC | Sphere 3D Corp.ANY | Spherix IncorporatedSPEX | Spirit Airlines, Inc.SAVE | Splunk Inc.SPLK | Spok Holdings, Inc.SPOK | Sportsman's Warehouse Holdings, Inc.SPWH |